Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned initiation date changed from 30 Oct 2017 to 30 Jan 2018.
- 05 Oct 2017 New trial record